Use of antihypertensive drugs generates pressure-packed debate in COVID-19 eraResearchers have been trying to understand a possible link between blood pressure medications and COVID-19 Antihypertensive deprescribing may be possible in some older patients with hypertensionNo substantial change in short-term blood pressure control, but long-term clinical outcomes uncertain 2020 Canadian hypertension guidelines now available, with separate guidelines for managing resistant cases Provide expert guidance on the prevention, diagnosis, risk assessment and treatment of hypertension in adults and children Allerject voice-assisted epinephrine autoinjector back to Canadian market Second epinephrine autoinjector provides patients with an alternative to EpiPen in managing anaphylaxis Acetaminophen may interact with warfarin leading to high INR and bleeding Higher acetaminophen doses over prolonged periods puts patients at greater risk Hypertension professional certification program for pharmacists now available Hypertension Canada program provides pharmacists with knowledge and confidence to identify and manage patients with hypertension Bristol-Myers Squibb discontinues Coumadin brand of warfarin Generic alternatives still marketed, but some strengths of one generic product currently in short supply Chlorthalidone not preferred over hydrochlorothiazide for hypertension treatment Study finds no difference in cardiovascular benefits, but greater risk of renal and electrolyte abnormalities with chlorthalidone New Canadian guideline on low-dose ASA for prevention of vascular events ASA no longer recommended for primary prevention in individuals without a history of symptomatic cardiovascular disease, stroke or peripheral artery disease Watch for calcium channel blocker–loop diuretic prescribing cascade in older hypertensive patients Ontario study finds higher incidence of loop diuretic prescribing in older adults started on CCBs compared to ACEIs, ARBs or other meds First Previous 33 34 35 36 37 Next Last
